Edward V Loftus

33PUBLICATIONS
119CO-AUTHORS
RehabilitationCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Molecular targetsSocio-economic development
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (33)

|May 05, 2026
Improvement in Health-Related Quality of Life in Patients with Moderate to Severe Crohn's Disease Treated with Risankizumab vs Ustekinumab in the Phase 3B SEQUENCE Study.

|Mar 30, 2026
Symptom Response Dynamics for Personalised Therapy with Subcutaneous Infliximab in Crohn's Disease: Insights from the Randomised, Placebo-Controlled, Phase 3 LIBERTY-CD Trial.

Stefan Schreiber, Bruce E Sands, Silvio Danese

|Nov 28, 2025
One Subcutaneous 2-ml Injection of Mirikizumab is Bioequivalent to Two 1-ml Subcutaneous Injections in Healthy Participants.

Yuki Otani, Christopher D Payne, Edward V Loftus

|May 12, 2025
Deucravacitinib in patients with inflammatory bowel disease: 12-week efficacy and safety results from 3 randomized phase 2 studies in Crohn's disease and ulcerative colitis.

Geert D'Haens, Silvio Danese, Remo Panaccione

|Apr 30, 2025
Global evolution of inflammatory bowel disease across epidemiologic stages.

Lindsay Hracs, Joseph W Windsor, Julia Gorospe

|Apr 01, 2025
Corticosteroid-sparing effects of risankizumab efficacy and safety in patients with moderately to severely active ulcerative colitis.

Walter Reinisch, Edward V Loftus, Stefan Schreiber

Pageof 6

Frequent Collaborators

8 joint publications

Silvio Danese

5 joint publications

David T Rubin

5 joint publications

Jean-Frederic Colombel

5 joint publications

Remo Panaccione